$ZBH

Zimmer: Q3 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

Original reporting
Published Nov 4, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zimmer: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$ZBHBullishHigh
01

Why it matters

Earnings beat and raised guidance provide a fresh catalyst for the stock.

02

Market read

The earnings surprise may drive short-term buying interest in ZBH and related medical device stocks.

03

What to watch

Potential supply chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Zimmer Biomet is a leading orthopedic device manufacturer.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet reported Q3 profit of $191.6M, EPS $1.00 beating $1.89 consensus and revenue $2.06B beating $2.05B estimates.

Expected impact

likely upward as market prices in the earnings beat and higher guidance

Evidence & confidence

Both earnings and revenue exceeded expectations, and full-year guidance was raised, providing a clear catalyst for price appreciation.

Market effects

Positive earnings may lift the broader orthopedic device sector.

U.S. healthcare stocks could see modest gains.

Limited to investors focused on medical device equities.

Counterpoint

If the beat is already priced in, the stock could face short-term profit-taking.

Key entities

  • Zimmer Biomet Holdings Inc.

    Orthopedic device maker reporting Q3 results.

Related articles

$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

$ZBHHighAI 8/10

Zimmer Biomet beats Q3 estimates, raises guidance

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

$ZBHHighAI 8/10

Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 2026 revenue of $2.06B, beating estimates by 1.1% and growing 3.1% YoY. Adjusted EPS was $1.90, a 1% beat. Management raised full-year adjusted EPS guidance to $8.55. Operating margin declined to 14.9%, while free cash flow margin increased to 18.1%. Constant currency revenue grew 3.7% YoY, down from 8.6% last quarter.

$ZBHHighAI 8/10

Zimmer Biomet Q3 Sales Rise 3.1%; Raises 2026 Growth Guidance

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.